ArticleJournal of Crohn's & colitis2025

Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies.

Raja Atreya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.